• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/7/24 12:31:17 PM ET
    $AFIB
    $ALLR
    $BVS
    $DSGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFIB alert in real time by email

    Gainers

    • Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today.
    • Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today.
    • Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million.
    • Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million.
    • Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market value of their outstanding shares is at $5.9 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 22.61% to $1.2.

    Losers

    • Neuronetics (NASDAQ:STIM) stock declined by 33.1% to $2.51 during Tuesday's regular session. The company's market cap stands at $75.2 million. As per the news, the Q1 earnings report came out today.
    • Helius Medical Tech (NASDAQ:HSDT) shares decreased by 25.62% to $1.8. The market value of their outstanding shares is at $1.5 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock declined by 20.08% to $0.72. The market value of their outstanding shares is at $1.7 million.
    • Lyra Therapeutics (NASDAQ:LYRA) stock fell 17.86% to $0.43. The market value of their outstanding shares is at $26.1 million.
    • GlucoTrack (NASDAQ:GCTK) stock decreased by 16.28% to $0.64. The market value of their outstanding shares is at $17.1 million.
    • Talkspace (NASDAQ:TALK) stock declined by 15.1% to $2.7. The company's market cap stands at $458.0 million. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB
    $ALLR
    $BVS
    $DSGN

    CompanyDatePrice TargetRatingAnalyst
    Design Therapeutics Inc.
    $DSGN
    3/16/2026$15.00Buy
    Jefferies
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    Design Therapeutics Inc.
    $DSGN
    1/7/2026$18.00Outperform
    Oppenheimer
    Talkspace Inc.
    $TALK
    12/9/2025$3.50Equal Weight
    Barclays
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$14.00Market Perform → Outperform
    Leerink Partners
    Design Therapeutics Inc.
    $DSGN
    12/3/2025$15.00Buy
    Craig Hallum
    Design Therapeutics Inc.
    $DSGN
    11/20/2025$13.00Sector Perform → Outperform
    RBC Capital Mkts
    Talkspace Inc.
    $TALK
    10/31/2025$5.00Hold → Buy
    Needham
    More analyst ratings

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sullivan Keith J

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/18/26 4:34:30 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Pfanstiel Steven

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/18/26 4:33:52 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Macan William Andrew

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/18/26 4:34:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Design Therapeutics with a new price target

    Jefferies initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00

    3/16/26 8:40:28 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Design Therapeutics with a new price target

    Oppenheimer initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $18.00

    1/7/26 9:09:56 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

    REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The Annual Report on Form 10-K, including audited financial statements fo

    3/17/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuwellis Completes Acquisition of Rendiatech

    MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card

    3/17/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM

    3/17/26 7:50:00 AM ET
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    SEC Filings

    View All

    SEC Form S-3 filed by Neuronetics Inc.

    S-3 - Neuronetics, Inc. (0001227636) (Filer)

    3/17/26 4:54:24 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/17/26 9:13:10 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Neuronetics Inc.

    10-K - Neuronetics, Inc. (0001227636) (Filer)

    3/17/26 8:00:33 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Harris Ian Jiro bought $86,037 worth of shares (30,844 units at $2.79), increasing direct ownership by 5% to 615,015 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/5/25 4:00:06 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Cohen Jon R bought $214,500 worth of shares (75,000 units at $2.86), increasing direct ownership by 3% to 2,267,980 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/3/25 9:30:03 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Chief Legal Officer, Secretary Reilly John Charles bought $10,242 worth of shares (3,600 units at $2.85), increasing direct ownership by 0.41% to 889,806 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    2/28/25 9:55:04 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

    SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

    12/16/24 9:02:59 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Leadership Updates

    Live Leadership Updates

    View All

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    $ALLR
    $BVS
    $DSGN
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

    DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/24/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care